LQDA trades 69.7% below Wall Street's consensus target of $72.36.
Last 12 months price action with 12-month analyst target path
The base valuation assumes LQDA achieves its forward estimates and maintains a stable P/E multiple of 20.4x. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 25, 2026, Liquidia Corporation (LQDA) has a Wall Street consensus price target of $72.36, based on estimates from 9 covering analysts. With the stock currently trading at $42.65, this represents a potential upside of +69.7%. The company has a market capitalization of $3.79B.
Analyst price targets range from a low of $33.00 to a high of $130.00, representing a 134% spread in expectations. The median target of $65.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, LQDA trades at a trailing P/E of -53.3x and forward P/E of 20.4x. Analysts expect EPS to grow +53.0% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $8.75, with bear and bull scenarios of $5.51 and $11.53 respectively. Model confidence stands at 45/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 UTHRUnited Therapeutics Corporation | $24.9B | $587.50 | $651.63 | +10.9% | Buy | 22.1x | 31 |
 MNKDMannKind Corporation | $1.0B | $3.19 | $10.00 | +213.5% | Buy | — | 21 |
 INVAInnoviva, Inc. | $1.5B | $20.66 | $38.00 | +83.9% | Buy | 8.5x | 10 |
 PRAXPraxis Precision Medicines, Inc. | $7.1B | $252.96 | $611.69 | +141.8% | Buy | — | 18 |
 INSMInsmed Incorporated | $20.2B | $93.39 | $193.60 | +107.3% | Buy | — | 36 |
 NKTRNektar Therapeutics | $1.2B | $37.22 | $121.33 | +226.0% | Buy | — | 33 |
 PBYIPuma Biotechnology, Inc. | $561M | $11.02 | — | — | Buy | 29.0x | 20 |
 KALAKALA BIO, Inc. | $4M | $0.19 | $18.25 | +9500.2% | Buy | — | 9 |
 JNJJohnson & Johnson | $635.0B | $263.81 | $285.31 | +8.1% | Buy | 23.7x | 40 |
 MRKMerck & Co., Inc. | $358.8B | $145.27 | $157.94 | +8.7% | Buy | 54.8x | 38 |
Quick answers to the most common questions about buying LQDA stock.
The consensus Wall Street price target for LQDA is $72.36, representing 69.7% upside from the current price of $42.65. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
LQDA has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $72.36 implies 69.7% upside from current levels.
LQDA trades at a forward P/E of 20.394x, representing a moderate valuation. With analysts targeting $72.36 (69.7% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $130 for LQDA, while the most conservative target is $33. The consensus of $72.36 represents the median expectation. Our quantitative valuation model projects a bull case target of $12 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
LQDA is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 2 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month LQDA stock forecast based on 9 Wall Street analysts shows a consensus price target of $72.36, with estimates ranging from $33 (bear case) to $130 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $9, with bear/bull scenarios of $6/$12.
Our quantitative valuation model calculates LQDA's fair value at $9 (base case), with a bear case of $6 and bull case of $12. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 45/100.
LQDA trades at a forward P/E ratio of 20.4x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on LQDA, with a "Buy" consensus rating and $72.36 price target (69.7% upside). 6 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
LQDA analyst price targets range from $33 to $130, a 134% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $72.36 consensus represents the middle ground. Our model's $6-$12 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.